Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore Read More →
Moving from Precision Medicine to Personalized Drugs to Fight Driver Mutations in Cancer with Usama Malik Fore Biotherapeutics Read More →
High MAPK Activity May Predict MEK Inhibitor Benefit for RAS-Mutated Cancer Patients, Study Finds Read More →
NovellusDx Registers Another Patent on their FACT™ system,Publishes a New Study With Guardent Health and MD Anderson InCancer Discovery; Was Selected To Present At BioMed, BIO 2017 andASCO Read More →
NovellusDx Establishes Fore Biotherapeutics U.S. as its OperatingCompany in the United States & Appoints Dieter Weinand asChairman of the Board & Usama Malik as Chief Executive Officer andDirector of the Board Read More →
Novellus Executes Exclusive Worldwide License Agreement withPlexxikon for PLX8394, Plexxikon’s Next-Generation, Clinical StageBRAF Inhibitor Read More →
New partnership between Christiana Care’s Gene Editing Institute and NovellusDx speeds progress toward personalized cancer medicine Read More →
